<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Keros Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/keros-therapeutics-inc</link>
<description>Latest news and press releases for Keros Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 09 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/keros-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68358ec778dffbe2df1015b0.webp</url>
<title>Keros Therapeutics Inc</title>
<link>https://6ix.com/company/keros-therapeutics-inc</link>
</image>
<item>
<title>Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS</title>
<link>https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-announces-collaboration-with-sean-m-healey-and-amg-center-for-als</link>
<guid isPermaLink="true">https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-announces-collaboration-with-sean-m-healey-and-amg-center-for-als</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical</description>
</item>
<item>
<title>Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-reports-recent-business-highlights-and-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-reports-recent-business-highlights-and-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Wed, 04 Mar 2026 21:01:00 GMT</pubDate>
<description>LEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended Decembe</description>
</item>
<item>
<title>Keros Therapeutics Appoints Charles Newton to its Board of Directors</title>
<link>https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-appoints-charles-newton-to-its-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-appoints-charles-newton-to-its-board-of-directors</guid>
<pubDate>Thu, 26 Feb 2026 21:01:00 GMT</pubDate>
<description>LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced the appointment of Charles Newton to its Board of Directors, effective March 9, 2026. “We are pleas</description>
</item>
<item>
<title>Keros Therapeutics Announces Final Results of Tender Offer</title>
<link>https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-announces-final-results-tender-offer-2025-11-20</link>
<guid isPermaLink="true">https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-announces-final-results-tender-offer-2025-11-20</guid>
<pubDate>Thu, 20 Nov 2025 05:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the final results of</description>
</item>
<item>
<title>Keros Therapeutics Announces Preliminary Results of Tender Offer</title>
<link>https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-announces-preliminary-results-tender-offer-2025-11-19</link>
<guid isPermaLink="true">https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-announces-preliminary-results-tender-offer-2025-11-19</guid>
<pubDate>Wed, 19 Nov 2025 05:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the preliminary</description>
</item>
<item>
<title>Keros Therapeutics Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-reports-third-quarter-2025-financial-results-2025-11-05</link>
<guid isPermaLink="true">https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-reports-third-quarter-2025-financial-results-2025-11-05</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical</description>
</item>
<item>
<title>Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares</title>
<link>https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-commences-issuer-tender-offer-repurchase-1944-million-shares-2025</link>
<guid isPermaLink="true">https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-commences-issuer-tender-offer-repurchase-1944-million-shares-2025</guid>
<pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical</description>
</item>
<item>
<title>Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital</title>
<link>https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-announces-plan-return-375-million-excess-capital-2025-10-15</link>
<guid isPermaLink="true">https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-announces-plan-return-375-million-excess-capital-2025-10-15</guid>
<pubDate>Wed, 15 Oct 2025 04:00:00 GMT</pubDate>
<description>Agrees to Repurchase of All Shares Held By ADAR1 Capital Management and Pontifax Venture Capital Plans to Commence Tender Offer to Repurchase up to $194</description>
</item>
<item>
<title>Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting</title>
<link>https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-presents-additional-clinical-data-its-ker-065-program-american</link>
<guid isPermaLink="true">https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-presents-additional-clinical-data-its-ker-065-program-american</guid>
<pubDate>Mon, 08 Sep 2025 04:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on</description>
</item>
<item>
<title>Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences</title>
<link>https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-announces-participation-upcoming-healthcare-conferences-2025-08-28</link>
<guid isPermaLink="true">https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-announces-participation-upcoming-healthcare-conferences-2025-08-28</guid>
<pubDate>Thu, 28 Aug 2025 04:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical</description>
</item>
<item>
<title>Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy</title>
<link>https://6ix.com/company/keros-therapeutics-inc/news/keros-announces-us-fda-orphan-drug-designation-granted-ker-065-treatment-duchenne</link>
<guid isPermaLink="true">https://6ix.com/company/keros-therapeutics-inc/news/keros-announces-us-fda-orphan-drug-designation-granted-ker-065-treatment-duchenne</guid>
<pubDate>Wed, 20 Aug 2025 04:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on</description>
</item>
<item>
<title>Keros to Exclusively Prioritize the Clinical Advancement of KER-065</title>
<link>https://6ix.com/company/keros-therapeutics-inc/news/keros-exclusively-prioritize-clinical-advancement-ker-065-2025-08-06</link>
<guid isPermaLink="true">https://6ix.com/company/keros-therapeutics-inc/news/keros-exclusively-prioritize-clinical-advancement-ker-065-2025-08-06</guid>
<pubDate>Wed, 06 Aug 2025 04:00:00 GMT</pubDate>
<description>Company Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and</description>
</item>
<item>
<title>Keros Therapeutics Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-reports-second-quarter-2025-financial-results-2025-08-06</link>
<guid isPermaLink="true">https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-reports-second-quarter-2025-financial-results-2025-08-06</guid>
<pubDate>Wed, 06 Aug 2025 04:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical</description>
</item>
<item>
<title>Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept</title>
<link>https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-announces-first-patient-dosing-phase-3-renew-clinical-trial</link>
<guid isPermaLink="true">https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-announces-first-patient-dosing-phase-3-renew-clinical-trial</guid>
<pubDate>Thu, 17 Jul 2025 04:00:00 GMT</pubDate>
<description>Milestone payment of $10 million triggered under the global license agreement with Takeda LEXINGTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Keros</description>
</item>
<item>
<title>Keros Announces Return of $375 Million in Excess Capital to Stockholders</title>
<link>https://6ix.com/company/keros-therapeutics-inc/news/keros-announces-return-375-million-excess-capital-stockholders-2025-06-09</link>
<guid isPermaLink="true">https://6ix.com/company/keros-therapeutics-inc/news/keros-announces-return-375-million-excess-capital-stockholders-2025-06-09</guid>
<pubDate>Mon, 09 Jun 2025 04:00:00 GMT</pubDate>
<description>Concludes Strategic Alternatives Review and Provides Update on Development of KER-065 LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics,</description>
</item>
<item>
<title>Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference</title>
<link>https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-announces-participation-goldman-sachs-46th-annual-global</link>
<guid isPermaLink="true">https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-announces-participation-goldman-sachs-46th-annual-global</guid>
<pubDate>Fri, 06 Jun 2025 04:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on</description>
</item>
<item>
<title>Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring</title>
<link>https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-announces-tropos-topline-data-and-corporate-restructuring-2025-05</link>
<guid isPermaLink="true">https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-announces-tropos-topline-data-and-corporate-restructuring-2025-05</guid>
<pubDate>Thu, 29 May 2025 04:00:00 GMT</pubDate>
<description>Discontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities LEXINGTON, Mass., May</description>
</item>
<item>
<title>Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros’ Director Nominees</title>
<link>https://6ix.com/company/keros-therapeutics-inc/news/leading-independent-proxy-advisory-firm-glass-lewis-recommends-stockholders-vote-all</link>
<guid isPermaLink="true">https://6ix.com/company/keros-therapeutics-inc/news/leading-independent-proxy-advisory-firm-glass-lewis-recommends-stockholders-vote-all</guid>
<pubDate>Tue, 27 May 2025 04:00:00 GMT</pubDate>
<description>Keros Board Best Equipped to Oversee Strategic Review Process and Execute on Ultimate Outcome of that Process ADAR1’s Disruptive and Self-Serving Campaign</description>
</item>
<item>
<title>ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth</title>
<link>https://6ix.com/company/keros-therapeutics-inc/news/adar1-announces-iss-recommends-keros-therapeutics-stockholders-withhold-votes-from-directors-dr-mary-ann-gray-and-dr-alpna-seth</link>
<guid isPermaLink="true">https://6ix.com/company/keros-therapeutics-inc/news/adar1-announces-iss-recommends-keros-therapeutics-stockholders-withhold-votes-from-directors-dr-mary-ann-gray-and-dr-alpna-seth</guid>
<pubDate>Wed, 21 May 2025 12:00:00 GMT</pubDate>
<description>ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "We"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the "Company") with approximately 13.3% of the Company's outstanding shares, today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. ("ISS") has recommended that Keros stockholders WITHHOLD votes from incumbent directors Dr. Mary Ann Gray and Dr. Alpna Seth at the Company's upcoming Annual Meeting of S</description>
</item>
<item>
<title>Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value</title>
<link>https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-highlights-commitment-maximizing-stockholder-value-2025-05-19</link>
<guid isPermaLink="true">https://6ix.com/company/keros-therapeutics-inc/news/keros-therapeutics-highlights-commitment-maximizing-stockholder-value-2025-05-19</guid>
<pubDate>Mon, 19 May 2025 04:00:00 GMT</pubDate>
<description>Files Investor Presentation and Issues Open Letter to Stockholders Urges Stockholders to Protect the Value of Their Investment by Voting “FOR” Each of the</description>
</item>
</channel>
</rss>